MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 9:00 a.m. PT in San Francisco. A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com/. A replay will also be available within 24 hours for seven days following the presentation. About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/. CONTACT: Lisa Borland MAP Pharmaceuticals, Inc. (650) 386-3122 DATASOURCE: MAP Pharmaceuticals, Inc. CONTACT: Lisa Borland of MAP Pharmaceuticals, Inc., +1-650-386-3122 Web Site: http://www.mappharma.com/

Copyright